Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

SIGA Technologies Inc.

SIGANASDAQEQUITYCurrent

Annual Report

Filed Mar 12, 2024Accepted Mar 12, 2024, 5:00 PM EDTCIK 1010086Accession 0001437749-24-007487
Share

Company context

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Current securities

Recent company filings

  1. 10-Q filingAug 6, 2026
  2. Results of Operations and Financial ConditionAug 6, 2026
  3. S-8 filingJun 25, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersJun 10, 2026
  5. DEFA14A filingMay 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗